Last updated: July 31, 2026
Betaseron, the brand name for interferon beta-1b, is a mature multiple sclerosis therapy with no meaningful ongoing pivotal-development program, no remaining U.S. regulatory exclusivity, and declining commercial relevance. Its clinical value is established in relapsing forms of multiple sclerosis, but oral and high-efficacy disease-modifying therapies have displaced interferon beta products in new-patient treatment. Betaseron’s remaining market is concentrated in legacy patients, selected lower-risk treatment settings, and countries where price, reimbursement, or physician familiarity support continued use.
What is Betaseron and what is it approved to treat?
Betaseron is recombinant interferon beta-1b, administered by subcutaneous injection at 0.25 mg every other day after dose titration. The U.S. Food and Drug Administration approved it in 1993 for ambulatory patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations.[1]
| Attribute |
Betaseron profile |
| Active ingredient |
Interferon beta-1b |
| Dosage form |
Lyophilized powder for injection |
| Route |
Subcutaneous |
| Standard maintenance dose |
0.25 mg every other day |
| Original U.S. sponsor |
Berlex Laboratories, later Bayer |
| FDA approval |
1993 |
| Main indications |
Relapsing-remitting MS and related relapsing forms |
| Drug class |
Injectable disease-modifying therapy |
| Primary competitors |
Avonex, Rebif, Copaxone, Gilenya, Tecfidera, Aubagio, Mavenclad, Tysabri, Ocrevus, Kesimpta |
| Current development status |
No active pivotal Betaseron development program identified |
Betaseron is not a treatment for acute MS relapses. Corticosteroids are generally used for clinically significant relapses, while Betaseron is intended for long-term reduction of relapse activity.
What did the pivotal Betaseron clinical trials show?
The pivotal randomized trial established that interferon beta-1b reduced relapse frequency and delayed progression to a sustained disability endpoint compared with placebo in patients with relapsing-remitting MS.[2]
The trial evaluated two Betaseron doses, 0.05 mg and 0.25 mg, administered subcutaneously on alternate days. The higher dose produced the clinically relevant treatment effect and became the approved regimen. The study reported reductions in annualized relapse rate, fewer patients with confirmed disease progression, and lower numbers of new or enlarging MRI lesions.
Betaseron’s clinical evidence is strongest for:
- Reduction in relapse frequency.
- Reduction in MRI disease activity.
- Slowing of disability progression in a subset of patients.
- Long-term treatment of relapsing MS rather than progressive disease without relapses.
The treatment has important tolerability limitations. Flu-like symptoms, injection-site reactions, liver enzyme elevations, leukopenia, and depression are recognized risks. Neutralizing antibodies can reduce biological activity in some patients. These limitations became more commercially important as oral and infusion therapies entered the market.
What is the current Betaseron clinical-trial status?
There is no established late-stage clinical program aimed at expanding Betaseron’s label, improving its formulation, or repositioning interferon beta-1b for a new neurological indication. Historical trials continue to appear in scientific and registry records, but they do not represent a current commercial development program.
Historical trials and follow-on evidence
| Study or evidence area |
Main purpose |
Current relevance |
| North American pivotal trial |
Evaluated interferon beta-1b in relapsing-remitting MS |
Established efficacy and FDA approval |
| European comparative studies |
Assessed dose, relapse reduction, MRI activity, and tolerability |
Supported international use |
| BENEFIT study |
Evaluated early interferon beta-1b treatment after a first demyelinating event |
Supported earlier intervention in patients at high risk of MS |
| Long-term observational follow-up |
Examined disability, adherence, and treatment persistence |
Provides durability data but is not a registration program |
| Combination and sequencing studies |
Compared interferon-based treatment with other DMT strategies |
Limited current commercial impact |
The BENEFIT trial found that treatment after a first clinical event suggestive of MS reduced the risk and delayed the timing of clinically definite MS compared with placebo over the study period.[3] Its commercial effect has diminished because current practice increasingly uses MRI-defined risk assessment and more potent disease-modifying therapies.
When does Betaseron lose exclusivity?
Betaseron lost meaningful U.S. market exclusivity many years ago. The original small-molecule-style patent and regulatory exclusivity framework does not provide a current barrier to competition comparable to a recently approved drug.
Betaseron is a biologic product, but its commercial protection is weaker than that of newer biologics because:
- The product was approved before the modern U.S. biosimilar pathway existed.
- Its key clinical and formulation technologies are mature.
- Interferon beta products have long been marketed by multiple companies.
- The main competitive threat is therapeutic substitution, not only biosimilar entry.
U.S. patent and regulatory position
| Protection category |
Betaseron position |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Expired or not commercially relevant |
| Primary product patents |
Expired or commercially exhausted |
| Orange Book protection |
No meaningful current exclusivity barrier |
| Biologics reference-product exclusivity |
Expired under any commercially relevant interpretation |
| Current patent risk |
Low for the original product; potentially higher for novel delivery or manufacturing technologies |
The Orange Book is primarily relevant to small-molecule drug applications. Betaseron’s biological product history means that biologics licensing records and jurisdiction-specific patent registers are more relevant than Orange Book listings alone.[4]
What patents protect Betaseron and interferon beta-1b?
The original Betaseron estate included patents and regulatory rights covering recombinant interferon beta-1b production, formulation, dosing, and use in multiple sclerosis. Those rights are no longer a material barrier to ordinary interferon beta-1b competition.
Current patent value would be concentrated in later-generation technologies such as:
- Long-acting interferon formulations.
- Sustained-release injection systems.
- Stability-enhancing excipients.
- Prefilled syringes and autoinjectors.
- Manufacturing processes that improve yield or reduce aggregation.
- Combination regimens involving interferon beta-1b.
- Patient-selection or biomarker methods.
A competitor seeking to launch a conventional interferon beta-1b product would face manufacturing validation, comparability, quality-control, pharmacovigilance, and reimbursement barriers rather than a strong blocking patent estate. The manufacturing process remains technically demanding because recombinant protein consistency, potency, glycosylation profile, impurity control, and product stability must be demonstrated.
What is the FDA regulatory status of Betaseron?
Betaseron remains an established FDA-approved therapy for relapsing forms of MS, subject to product availability and sponsor commercial decisions. FDA labeling identifies warnings and precautions involving depression and suicidal ideation, hepatic injury, hematologic abnormalities, injection-site necrosis, anaphylaxis, and flu-like reactions.[1]
The main regulatory issues are no longer approval of the original indication. They are:
- Continued compliance with biologics manufacturing requirements.
- Stability and sterility of the injectable product.
- Postmarketing safety surveillance.
- Labeling of new delivery devices.
- Product discontinuation or supply changes.
- Any future biosimilar or interchangeable-product pathway.
No new FDA label expansion is central to Betaseron’s commercial outlook.
What is the Orange Book status of Betaseron?
Betaseron should not be analyzed as a conventional Orange Book patent-protected small molecule. The product’s competitive position depends primarily on biologics regulation, historical licensing rights, manufacturing capability, and market access.
The absence of a material current Orange Book barrier means that a generic-style patent challenge is not the principal launch pathway. A competing interferon beta-1b product would more likely proceed through an applicable biologics or follow-on regulatory route, depending on the product’s jurisdiction and reference-product classification.
Which companies compete with Betaseron?
Betaseron competes in two separate markets: the interferon beta market and the broader MS disease-modifying therapy market.
Direct interferon competitors
| Product |
Active ingredient |
Administration |
Competitive position |
| Extavia |
Interferon beta-1b |
Subcutaneous |
Same active ingredient; historically positioned as an alternative to Betaseron |
| Avonex |
Interferon beta-1a |
Intramuscular |
Once-weekly dosing |
| Rebif |
Interferon beta-1a |
Subcutaneous |
More frequent dosing, established efficacy |
| Plegridy |
Peginterferon beta-1a |
Subcutaneous |
Less frequent dosing and improved convenience |
Broader MS competitors
Oral products such as dimethyl fumarate, diroximel fumarate, teriflunomide, fingolimod, and cladribine compete on convenience. High-efficacy therapies such as natalizumab, ocrelizumab, ofatumumab, and other anti-CD20 products compete on disease control and treatment escalation.
The primary commercial disadvantage for Betaseron is the combination of alternate-day injections, flu-like reactions, and lower perceived efficacy relative to newer high-efficacy therapies.
How strong is the Betaseron patent estate?
The original Betaseron patent estate is weak as a current commercial defense. Its strengths are historical rather than blocking.
| Patent-estate factor |
Assessment |
| Core composition protection |
Expired or exhausted |
| Original method-of-use protection |
Expired |
| Formulation protection |
Limited remaining value for legacy products |
| Device protection |
Relevant only to specific device configurations |
| Manufacturing know-how |
Moderate practical value |
| Regulatory exclusivity |
No meaningful remaining U.S. exclusivity |
| Litigation leverage |
Low |
| Generic or follow-on entry risk |
High in markets with regulatory and reimbursement support |
Manufacturing know-how can still delay competition. A follow-on manufacturer must demonstrate product quality and clinical or analytical comparability under the applicable regulatory framework. That barrier is operational, not a durable patent moat.
What generic or biosimilar entry risks exist for Betaseron?
Betaseron faces three forms of competition:
- Direct interferon beta-1b follow-on products.
- Interferon beta-1a and pegylated interferon products.
- Therapeutic substitution by oral and high-efficacy MS therapies.
A traditional Hatch-Waxman Paragraph IV challenge is not the central U.S. risk because Betaseron is a biologic product rather than a conventional small-molecule NDA product. The more relevant risk is a follow-on biologic or competing biological product that relies on analytical, clinical, or abbreviated evidence under the applicable regulatory pathway.
Biosimilar risk is technically feasible but commercially constrained. The market is already shrinking, and development costs may not be justified unless a manufacturer can win substantial share through low pricing, government procurement, or regional reimbursement.
What is the Betaseron market outlook?
Betaseron’s market outlook is structurally negative. The global MS disease-modifying therapy market remains large, but growth is concentrated in oral, monoclonal antibody, and high-efficacy treatments rather than legacy interferons.[5]
Market drivers
- New patients are increasingly treated with oral or high-efficacy therapies.
- Treatment guidelines and clinical practice have shifted toward earlier disease control.
- Injection burden reduces adherence and persistence.
- Generic and follow-on competition pressures price.
- Payers favor lower-cost alternatives only when clinical positioning is acceptable.
- Long-term interferon users may remain on treatment because of disease stability or physician preference.
Market projection
| Period |
Betaseron outlook |
| 2024-2025 |
Continued decline in new prescriptions and brand relevance |
| 2026-2028 |
Legacy-patient base becomes the principal demand source |
| 2029 onward |
Residual regional demand, subject to product availability and pricing |
| Global MS market |
Growth driven mainly by oral and high-efficacy DMTs, not Betaseron |
No reliable public source reports Betaseron revenue as a standalone global line item. Bayer reports products within broader business categories, and brand-level sales data are not consistently disclosed. A defensible valuation should therefore model Betaseron through prescription volume, net price, country availability, and patient persistence rather than assign a market share based on total MS drug sales.
What revenue exposure does Betaseron create for Bayer?
Betaseron is unlikely to represent a material growth asset for Bayer. Its value is primarily residual cash flow from established users, assuming continued supply and commercial support.
Revenue exposure is limited by:
- Substitution by newer MS therapies.
- Low pricing in mature markets.
- Declining treatment starts.
- Potential discontinuation or reduced promotion.
- Competition from other interferon products.
- Manufacturing and supply-chain costs associated with injectable biologics.
For licensing or acquisition analysis, Betaseron should be treated as a harvest-stage product, not a platform asset. Upside would require a low-cost supply model, a differentiated device, or access to markets where injectable interferon remains reimbursed.
What litigation and settlement agreements affect Betaseron?
There is no major current U.S. patent litigation campaign surrounding Betaseron comparable to disputes involving recently launched specialty medicines. Historical disputes involving interferon beta products and biotechnology rights do not create a current, broad market barrier for the original Betaseron product.
No widely reported settlement agreement currently determines a future U.S. Betaseron launch date. Any launch analysis should focus on:
- Product availability notices.
- Regional regulatory approvals.
- Follow-on biologic applications.
- Manufacturing inspections.
- Supply and reimbursement contracts.
- Country-specific patent registers.
How does Betaseron compare with newer MS therapies?
| Factor |
Betaseron |
Newer oral or biologic DMTs |
| Administration |
Injection every other day |
Oral, monthly, semiannual, or other schedules |
| Efficacy positioning |
Moderate |
Often moderate to high, depending on product |
| Monitoring |
Blood counts and liver function |
Product-specific monitoring |
| Safety familiarity |
Long clinical history |
Varies by mechanism |
| Adherence burden |
High injection burden |
Generally lower administration burden |
| Patent protection |
Mature and weak |
Often substantial |
| Commercial growth |
Declining |
Concentrated in newer agents |
| Typical role |
Legacy therapy or selected lower-risk patients |
New starts, escalation, or high-efficacy treatment |
Key Takeaways
- Betaseron is interferon beta-1b, approved by the FDA in 1993 for relapsing forms of multiple sclerosis.
- Its pivotal evidence demonstrated reductions in relapse activity and MRI disease activity.
- No active pivotal development program is central to the product’s current outlook.
- U.S. regulatory exclusivity and meaningful core patent protection have expired.
- Orange Book analysis is less important than biologics licensing, manufacturing, and follow-on product regulation.
- The principal risks are therapeutic substitution, declining new starts, and lower-cost follow-on competition.
- Betaseron’s remaining value is concentrated in legacy patients and selected markets.
- The broader MS market can grow while Betaseron sales decline.
- A realistic projection treats Betaseron as a mature, contracting product with limited strategic upside.
FAQs
Is Betaseron still prescribed for multiple sclerosis?
Yes. It can remain appropriate for selected patients with relapsing MS, although prescribing has shifted toward oral and high-efficacy therapies.
Is interferon beta-1b the same as Betaseron?
Betaseron is a brand of interferon beta-1b. Extavia also contains interferon beta-1b, but brand, sponsor, regulatory history, and market availability may differ by country.
Can a company file a Paragraph IV challenge against Betaseron?
Paragraph IV is generally associated with Orange Book-listed patents for small-molecule products. Betaseron is a biologic, so follow-on biologic and biosimilar pathways are more relevant.
Does Betaseron have biosimilar competition?
The practical competitive threat comes from interferon beta follow-on products and therapeutic alternatives. The existence, designation, and commercial availability of a specific biosimilar depend on the jurisdiction.
What is the main barrier to launching a Betaseron competitor?
The main barriers are biologics manufacturing, analytical comparability, regulatory approval, supply reliability, reimbursement, and the declining size of the legacy interferon market.
References
-
U.S. Food and Drug Administration. (2023). Betaseron prescribing information. Bayer HealthCare Pharmaceuticals Inc.
-
The IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43(4), 655-661.
-
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E. W., Bauer, L., Lanius, V., Pohl, C., & Sandbrink, R. (2006). Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 67(7), 1242-1249.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
National Multiple Sclerosis Society. (2024). Disease-modifying therapies for multiple sclerosis. https://www.nationalmssociety.org/###
